While clinicians and HIV/AIDS patients anxiously watch the trend of the virus developing resistance to multiple antiretroviral therapies, the question remains whether new drug research will continue to save the day. Some suggest there will need to be multiple new classes of antiretroviral drugs developed in order to stretch further the life span of longtime HIV patients. One potential new class would target the Rev protein, an approach that has received very little attention from the research and pharmaceutical communities.